10 Activist Target Stocks with High Cash and Low Valuation
Activist investor activity has been high amid the heightened volatility in the equity markets in 2026.
Bio-Rad Laboratories Inc. (BIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 114,719 | $43,330,513 | -2% | 0.01% |
| 2. | Hosking Partners Jeremy Hosking | 95,472 | $36,060,729 | +2% | 1.28% |
| 3. | Sivik Global Healthcare Krishen Sud | 8,000 | $3,021,680 | -20% | 1.73% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 4,605 | $1,739,355 | 0.01% | |
| 5. | Antipodes Partners Jacob Mitchell | 85 | $32,105 | -25% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $219.58 | 500 | $109,792.45 | 500 | 2017-05-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $246.54 | 550 | $135,597.00 | 346 | 2026-05-11 | Filing | |
| $306.18 | 700 | $214,288.51 | 510 | 2025-11-06 | Filing | |
| $247.06 | 3,000 | $741,184.20 | 8,171 | 2025-03-14 | Filing | |
| $329.94 | 3,000 | $989,815.20 | 7,559 | 2024-09-06 | Filing | |
| $330.49 | 623 | $205,898.14 | 147 | 2024-09-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 885,977 | $334,645,742 | 0.06% | |
| 2. | 342,553 | $129,418,388 | 0.01% | |
| 3. | 322,152 | $121,680,033 | 0.02% | |
| 4. | 147,506 | $55,714,491 | 0.05% | |
| 5. | 114,662 | $43,309,063 | 0.01% |
News See All
Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says
Ariel Investments, an investment management company, released its "Ariel Appreciation Fund" Q3 2026 investor letter. A copy of the letter can be downloaded here. Copy main article 1st para.
BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount?
Is BIO a good stock to buy? We came across a bullish thesis on Bio-Rad Laboratories, Inc. on One Idea Per Day’s Substack by Paul.
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results.
Earnings Standouts: 52 Stocks Outperforming Wall Street Estimates
Research by the Bank for International Settlements said that equity markets tend to already price in earnings expectations well before official results are announced.
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out
Ariel Investments, an investment management company, released its “Ariel Focus Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2026 Earnings Call Transcript May 1, 2026 Operator: Ladies and gentlemen, thank you for standing by.
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Bio-Rad Laboratories, Inc. is among the most undervalued stocks to invest in.
9 Most Undervalued Healthcare Stocks to Buy Now
In this article, we will be taking a look at the 9 Most Undervalued Healthcare Stocks to Buy Now.
Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here.
Hedge Fund Resource Center